SHAREHOLDER ALERT: Levi & Korsinsky Notifies Kenvue Inc.(KVUE) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Oct. 19, 2023

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kenvue investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Kenvue securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Kenvue's May 2023 initial public offering. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/kenvue-lawsuit-submission-form?prid=52113&wire=4

KVUE investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Kenvue faces potential headwinds as a result of confirmed concerns about the efficacy of phenylephrine, which it knew or should have known; (2) Kenvue did not discuss risks relating to the efficacy of phenylephrine (or "PE") in its IPO, the utility of which had been questioned since at least 2007; (3) while the Company disclosed risks relating to litigation, it did not disclose specific risk relating to potential litigation arising from adverse findings on the efficacy of phenylephrine; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.

WHAT'S NEXT? If you suffered a loss in Kenvue during the relevant time frame, you have until December 8, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.